Buserelin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Buserelin: From GnRH Agonist Therapy to Hypertrichosis
One-Sentence Summary
Buserelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist whose established pharmacological role involves suppression of pituitary gonadotropins and downstream sex hormones; no UK marketing authorisation data is available within this evidence pack. The TxGNN model predicts it may be effective for Hypertrichosis, with 0 clinical trials and 1 publication currently supporting this direction. The mechanistic connection is considered weak, and the overall evidence basis is insufficient to progress beyond early signal assessment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No UK marketing authorisation on record in this evidence pack |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Buserelin is a synthetic GnRH (gonadotropin-releasing hormone) analogue. When administered continuously, it initially stimulates then chronically suppresses pituitary secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH), ultimately producing a significant reduction in circulating sex hormones — testosterone in males and oestrogen/progesterone in females. This “medical castration” effect underpins its established use in hormone-sensitive conditions.
Hypertrichosis is defined as abnormal or excessive hair growth beyond the accepted limits of normal for a given age, sex, and ethnicity. It is clinically distinct from hirsutism: hypertrichosis may occur in androgen-independent patterns across the whole body, often driven by structural genetic defects (e.g., KATP channel mutations in Cantú syndrome, or hair follicle differentiation gene defects in Ambras syndrome). The sole supporting publication in this evidence pack describes a Cantú syndrome patient presenting with multiple pituitary hormone deficiencies — a condition that shares hypertrichosis as a phenotypic feature but is mechanistically driven by ABCC9/KCNJ8 mutations, not by the GnRH–gonadotropin axis.
A theoretical mechanistic link exists only for the narrow androgen-dependent subset of hypertrichosis (i.e., androgenetic aetiology), where GnRH-mediated androgen suppression could attenuate hair follicle stimulation. However, the primary predicted target — generalised, non-androgen-dependent hypertrichosis — does not involve the GnRH pathway in its pathogenesis. The TxGNN knowledge graph model likely identified this association through shared rare syndrome co-morbidities (e.g., hypogonadism comorbid with hypertrichosis syndromes) rather than a direct therapeutic mechanism. The mechanistic link is assessed as weak.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31743099 | 2019 | Case Report | Endocrinology, Diabetes & Metabolism Case Reports | Cantú syndrome (hypertrichotic osteochondrodysplasia) case presenting with growth deceleration at age 13 leading to identification of multiple pituitary hormone deficiencies; supports inclusion of endocrine monitoring in clinical surveillance of this condition but does not evaluate Buserelin as a therapeutic agent for hypertrichosis |
UK Market Information
Buserelin currently holds no MHRA marketing authorisation in the United Kingdom according to the data provided in this evidence pack. No product licences, approved indications, or dosage forms are on record. Clinicians should consult the MHRA product licence register and the current BNF (Section 8.3.4 — Gonadorelin analogues and antagonists) independently to verify current licensing status before any clinical consideration.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).
Note for prescribers: GnRH agonists as a class are associated with bone mineral density reduction during prolonged use, hot flushes, and effects on libido and sexual function. In the context of the predicted indication (hypertrichosis), the known adverse effect of GnRH agonists on bone density would be particularly relevant, as some hypertrichosis syndromes (e.g., Cantú syndrome) already carry skeletal and metabolic comorbidities.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic connection between Buserelin’s GnRH-suppressive action and generalised non-androgen-dependent hypertrichosis is biologically implausible based on current understanding; supporting evidence consists solely of one case report describing a related syndrome rather than any therapeutic evaluation of Buserelin in this condition.
To proceed, the following is needed:
- Mechanistic validation: Peer-reviewed evidence confirming a GnRH–androgen pathway contribution to the specific subtype of hypertrichosis under investigation (androgen-dependent vs. genetic/structural forms must be distinguished)
- Clinical evidence generation: At minimum, a controlled observational study or case series demonstrating therapeutic effect of Buserelin or another GnRH analogue in hypertrichosis (not merely hirsutism)
- UK regulatory status clarification: Verify current MHRA marketing authorisation status and obtain the full SmPC including warnings, contraindications, and special population data
- Safety data gap remediation: MHRA-approved SmPC warnings and contraindications (currently absent from this evidence pack) are required before any safety assessment can proceed
- Patient subgroup stratification: If further investigation is pursued, restrict scope to androgen-dependent hypertrichosis subtypes where a plausible pharmacological rationale exists
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All information should be verified against current MHRA guidance, the British National Formulary (BNF), and the relevant SmPC.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.